PSA levels and cancer detection rate by centre in the European Randomized Study of Screening for Prostate Cancer

European Journal of Cancer

Volumn 46, Issue 17, 2010, Pages 3053-3060

  Otto, S J ^a   Moss, S M ^b   Maattanen L ^c   Roobol, M ^a   Zappa, M ^d   Nelen, V ^e   Kwiatkowski, M ^f   Villers, A ^g   Hugosson, J ^h   Sanchez, A Berenguer ⁱ   De Koning, H J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c FINNISH CANCER REGISTRY   (Finland)

^d Unit of Epidemiology   (Italy)

^e Provinciaal Instituut voor Hygiene   (Belgium)

^f CANTONAL HOSPITAL AARAU   (Switzerland)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

Author keywords

Cancer detection; Prostate cancer; PSA; Screening; Underlying incidence

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BELGIUM; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER SCREENING; CONTROLLED STUDY; FINLAND; FRANCE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PRIORITY JOURNAL; PROSTATE CANCER; SPAIN; SWITZERLAND;

AGE FACTORS; AGED; BIOPSY; EARLY DETECTION OF CANCER; EUROPE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REFERRAL AND CONSULTATION; SAMPLE SIZE; SENSITIVITY AND SPECIFICITY;

EID: 78049479810     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.09.012     Document Type: Article

References (22)

1. F.H. Schroder, J. Hugosson, and M.J. Roobol Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320 1328
2. M.J. Roobol, M. Kerkhof, and F.H. Schroder Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC) Eur Urol 56 2009 584 591
3. D.M. Parkin, C.S. Muir, S.L. Whelan, Cancer incidence in five continents vol. VI 1992 International Agency for Research on Cancer Lyon
4. T. Sarkeala, A. Anttila, I. Saarenmaa, and M. Hakama Validity of process indicators of screening for breast cancer to predict mortality reduction J Med Screen 12 2005 33 37
5. S. Moss, and R. Blanks Calculating appropriate target cancer detection rates and expected interval cancer rates for the UK NHS Breast Screening Programme. Interval Cancer Working Group J Epidemiol Community Health 52 1998 111 115
6. H.J. de Koning, A. Auvinen, and A. Berenguer Sanchez Large-scale randomized prostate cancer screening trials: program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial Int J Cancer 97 2002 237 244
7. M.J. Roobol, F.H. Schröder, The European Randomized Study of Screening for Prostate Cancer (ERSPC): rationale, structure and preliminary results 1994-2003 BJU Int Suppl 92 2003 1 117
8. M. Kwiatkowski, A. Huber, and M. Moschopulos Prostate cancer screening: results of a prospective trial in Canton Aargau, Switzerland Swiss Med Wkly 134 2004 580 585
9. Parkin DM, Whelan SL, Ferlay J, Storm H. Cancer incidence in five continents, vol VII. Lyon: IARC Scientific Publications No.7; 2005.
10. J. Cuzick, R. Edwards, and N. Segnan Adjusting for non-compliance and contamination in randomized clinical trials Stat Med 16 1997 1017 1029
11. P.M. Beemsterboer, R. Kranse, H.J. de Koning, J.D. Habbema, and F.H. Schröder Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam) Int J Cancer 84 1999 437 441
12. M.J. Roobol, A. Grenabo, F.H. Schroder, and J. Hugosson Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam J Natl Cancer Inst 99 2007 1296 1303
13. S.J. Otto, F.H. Schroder, and H.J. de Koning Low all-cause mortality in the volunteer-based Rotterdam section of the European randomised study of screening for prostate cancer: self-selection bias? J Med Screen 11 2004 89 92
14. N. Perry, M. Broeders, and C. de Wolf European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition - summary document Ann Oncol 19 2008 614 622
15. A. Auvinen, L. Maattanen, and U.H. Stenman Lead-time in prostate cancer screening (Finland) Cancer Causes Control 13 2002 279 285
16. G. Draisma, R. Boer, and S.J. Otto Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer J Natl Cancer Inst 95 2003 868 878
17. H. Straatman, P.G. Peer, and A.L. Verbeek Estimating lead time and sensitivity in a screening program without estimating the incidence in the screened group Biometrics 53 1997 217 229
18. A. Auvinen, J. Raitanen, and S. Moss Test sensitivity in the European prostate cancer screening trial: results from Finland, Sweden, and the Netherlands Cancer Epidemiol Biomarkers Prev 18 2009 2000 2005
19. S.W. Duffy, and R. Gabe What should the detection rates of cancers be in breast screening programmes? Br J Cancer 92 2005 597 600
20. S. Ciatto, M. Zappa, and A. Villers Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening BJU Int 92 Suppl. 2 2003 97 100
21. F. Bray, J. Lortet-Tieulent, J. Ferlay, D. Forman, and A. Auvinen Prostate cancer incidence and mortality trends in 37 European countries: an overview Eur J Cancer 46 2010 3040 3052
22. R.G. Cremers, H.E. Karim-Kos, and S. Houterman Prostate cancer: trends in incidence, survival and mortality in the Netherlands, 1989-2006 Eur J Cancer 46 2010 2077 2087